This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump. Reason to buy: A potential paradigm shift That's where Recursion Pharmaceuticals comes in. Its AI algorithm is designed to test various clinical compounds against a library of human genes it contains. It helps predict which compounds are the most likely to be effective at treating various illnesses, thereby speeding up the discovery process and reducing the risk that drugs that enter clinical trials will fail so ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,615 ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,61 ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $9.38, reflecting a +0.43% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. Elsewhere, the Dow saw a downswing of 0.1%, while the tech-heavy Nasdaq appreciated by 0.16%.The biotechnology company's shares have seen an increase of 1.97% over the last month, not keeping up with the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83%.The upcomin ...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nominationBayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analy ...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, anal ...

Bill Oxford Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotechnology company that gained fame in July 2023 when it benefited from a $50 million investment by NVIDIA (NASDAQ:NVDA). As a result, the market cap doubled to around $3.2 billion as shown below, but, after some ups and downs, the stock has since retrenched and is trading at less than $9. Data by YCharts This thesis aims to show that it is a buy at the current price because Recursion operates more as a TechBio than biotech. The ...

phuttaphat tipsana/iStock via Getty Images Recursion Pharmaceuticals (NASDAQ:RXRX) is a drug discovery company that is leveraging the power of artificial intelligence to try and bring drugs to market more efficiently. While there are a number of companies pursuing a similar strategy, Recursion is differentiated by its holistic approach and the scale at which it is operating. This is somewhat risky given the cost involved and the fact that it is still an unproven approach. It could help to address the declin ...

The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value.Investing in growth stocks can lead to significant returns for investors in the long run. But oftentimes, the best returns come from smaller stocks, which have modest market values. These stocks can be risky options, but due to their low valuations, they tend to have the most room to rise higher if their businesses prove to be the real deal.One stock that is your typical high-risk, high-potential-reward optio ...